Viking Therapeutics (NASDAQ:VKTX) Announces Earnings Results

Viking Therapeutics (NASDAQ:VKTX) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.02), Bloomberg Earnings reports.

NASDAQ VKTX traded down $0.33 during mid-day trading on Friday, hitting $7.24. The stock had a trading volume of 1,603,835 shares, compared to its average volume of 2,493,284. The stock’s 50 day moving average is $8.12. Viking Therapeutics has a twelve month low of $6.97 and a twelve month high of $24.00. The company has a market capitalization of $521.63 million, a PE ratio of -18.10 and a beta of 2.30.

A number of hedge funds and other institutional investors have recently bought and sold shares of VKTX. Great West Life Assurance Co. Can acquired a new position in Viking Therapeutics in the 4th quarter valued at $53,000. Legal & General Group Plc grew its holdings in Viking Therapeutics by 38.0% in the 4th quarter. Legal & General Group Plc now owns 10,704 shares of the biotechnology company’s stock valued at $82,000 after buying an additional 2,945 shares in the last quarter. United Services Automobile Association purchased a new stake in Viking Therapeutics in the 4th quarter valued at $83,000. Barclays PLC grew its holdings in Viking Therapeutics by 114.7% in the 4th quarter. Barclays PLC now owns 11,647 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 91,118 shares in the last quarter. Finally, Wedbush Securities Inc. purchased a new stake in Viking Therapeutics in the 2nd quarter valued at $97,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have recently weighed in on VKTX shares. CIBC started coverage on Viking Therapeutics in a research note on Tuesday, July 16th. They set an “outperform” rating and a $12.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $31.00 target price on shares of Viking Therapeutics in a research note on Friday. Stifel Nicolaus started coverage on Viking Therapeutics in a research note on Tuesday, June 25th. They set a “buy” rating and a $14.00 target price for the company. Oppenheimer started coverage on Viking Therapeutics in a research note on Tuesday, July 16th. They set an “outperform” rating and a $12.00 target price for the company. Finally, BidaskClub raised Viking Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 4th. One research analyst has rated the stock with a sell rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $20.53.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.

Read More: Why are gap-down stocks important?

Earnings History for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.